Johnson & Johnson SEC filings JNJ
Johnson & Johnson has 1,000 filings in SEC EDGAR's recent list, going back to Aug 2, 2018. Its latest annual report, Form ARS, was filed on Mar 11, 2026 for the period ended Dec 28, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 21, 2026, covering the quarter ended Sep 27, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (results of operations). The company's fiscal year ends on January 3.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 21, 2026 | Sep 27, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 13, 2026 | Oct 13, 2026 |
| N-PX | Filing | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 28, 2026 | Jul 27, 2026 |
| 10-Q | Quarterly report | Jul 23, 2026 | Jun 28, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 15, 2026 | Jul 15, 2026 |
| 11-K | Employee savings plan report | Jun 25, 2026 | Dec 31, 2025 |
| 11-K | Employee savings plan report | Jun 25, 2026 | Dec 31, 2025 |
| SD | Specialized disclosure (conflict minerals) | May 27, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
Apr 28, 2026 | Apr 23, 2026 |
| 10-Q | Quarterly report | Apr 22, 2026 | Mar 29, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Apr 14, 2026 | Apr 14, 2026 |
| ARS | Annual report to shareholders | Mar 11, 2026 | Dec 28, 2025 |
| DEFA14A | Additional proxy material | Mar 11, 2026 | — |
| DEF 14A | Proxy statement | Mar 11, 2026 | Mar 11, 2026 |
| S-3ASR | Automatic shelf registration | Feb 11, 2026 | — |
| 10-K | Annual report | Feb 11, 2026 | Dec 28, 2025 |
| 8-K |
Current report
Results of operations
|
Jan 21, 2026 | Jan 21, 2026 |
| 10-Q | Quarterly report | Oct 22, 2025 | Sep 28, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Oct 14, 2025 | Oct 14, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 9, 2025 | Sep 8, 2025 |
| N-PX | Filing | Aug 26, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | Jul 24, 2025 | Jun 29, 2025 |
| 8-K |
Current report
Results of operations
|
Jul 16, 2025 | Jul 16, 2025 |
| 11-K | Employee savings plan report | Jun 24, 2025 | Dec 31, 2024 |
| 11-K | Employee savings plan report | Jun 24, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 10, 2025 | Jun 10, 2025 |
| SD | Specialized disclosure (conflict minerals) | May 28, 2025 | — |
| UPLOAD | Letter from the SEC | May 2, 2025 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Apr 30, 2025 | Apr 24, 2025 |
| 10-Q | Quarterly report | Apr 23, 2025 | Mar 30, 2025 |
| CORRESP | Letter to the SEC | Apr 23, 2025 | — |
| PX14A6G | Bowyer research - px14a6g | Apr 23, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2025 | — |
| 8-K |
Current report
Results of operations, Other events
|
Apr 15, 2025 | Apr 15, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 3, 2025 | Mar 31, 2025 |
| PX14A6G | Filing | Mar 20, 2025 | — |
| DEFA14A | Additional proxy material | Mar 12, 2025 | — |
| ARS | Annual report to shareholders | Mar 12, 2025 | Dec 29, 2024 |
| DEF 14A | Proxy statement | Mar 12, 2025 | Mar 12, 2025 |
| DFAN14A | Filing | Mar 7, 2025 | — |
| CERT | Nyse certification | Feb 28, 2025 | — |
| 8-A12B | Filing | Feb 26, 2025 | — |
| 8-K |
Current report
Other events
|
Feb 26, 2025 | Feb 26, 2025 |
| DFAN14A | Filing | Feb 25, 2025 | — |
| 424B2 | Prospectus | Feb 21, 2025 | — |
| 8-K |
Current report
Other events
|
Feb 20, 2025 | Feb 20, 2025 |
| 424B2 | Prospectus | Feb 19, 2025 | — |
| FWP | Free writing prospectus | Feb 19, 2025 | — |
| 424B5 | Prospectus supplement | Feb 19, 2025 | — |
| FWP | Free writing prospectus | Feb 18, 2025 | — |
| 424B5 | Prospectus supplement | Feb 18, 2025 | — |
| 10-K | Annual report | Feb 13, 2025 | Dec 29, 2024 |
| DFAN14A | Filing | Jan 22, 2025 | — |
| 8-K/A | Amended current report | Jan 22, 2025 | Jan 22, 2025 |
| 8-K |
Current report
Results of operations
|
Jan 22, 2025 | Jan 22, 2025 |
| DFAN14A | Filing | Jan 13, 2025 | — |
| 25-NSE | Delisting notice | Nov 6, 2024 | — |
| 10-Q | Quarterly report | Oct 23, 2024 | Sep 29, 2024 |
| 8-K |
Current report
Results of operations
|
Oct 15, 2024 | Oct 15, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 20, 2024 | Sep 20, 2024 |
| 8-K |
Current report
Officer or director change
|
Sep 10, 2024 | Sep 10, 2024 |
| N-PX | Filing | Aug 29, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Aug 26, 2024 | Aug 26, 2024 |
| 10-Q | Quarterly report | Jul 25, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Jul 17, 2024 | Jul 17, 2024 |
| 11-K/A | Filing | Jun 25, 2024 | Dec 31, 2023 |
| 11-K | Employee savings plan report | Jun 24, 2024 | Dec 31, 2023 |
| 11-K | Employee savings plan report | Jun 24, 2024 | Dec 31, 2023 |
| SD | Specialized disclosure (conflict minerals) | May 28, 2024 | — |
| CERT | Nyse certification | May 21, 2024 | — |
| 8-A12B | Filing | May 20, 2024 | — |
| 8-K |
Current report
Other events
|
May 20, 2024 | May 20, 2024 |
| 25-NSE | Delisting notice | May 20, 2024 | — |
| 8-K |
Current report
Other events
|
May 17, 2024 | May 17, 2024 |
| 424B2 | Prospectus | May 16, 2024 | — |
| 424B2 | Prospectus | May 15, 2024 | — |
| FWP | Free writing prospectus | May 14, 2024 | — |
| 424B5 | Prospectus supplement | May 14, 2024 | — |
| FWP | Free writing prospectus | May 14, 2024 | — |
| 424B5 | Prospectus supplement | May 13, 2024 | — |
| 10-Q | Quarterly report | May 1, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 1, 2024 | May 1, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Apr 29, 2024 | Apr 25, 2024 |
| 8-K/A | Amended current report | Apr 16, 2024 | Apr 16, 2024 |
| 8-K |
Current report
Results of operations, Other events
|
Apr 16, 2024 | Apr 16, 2024 |
| DFAN14A | Filing | Apr 5, 2024 | — |
| PX14A6G | National legal and policy center - px14a6g | Mar 27, 2024 | — |
| ARS | Annual report to shareholders | Mar 13, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Mar 13, 2024 | — |
| DEFA14A | Additional proxy material | Mar 13, 2024 | — |
| DEF 14A | Proxy statement | Mar 13, 2024 | Apr 25, 2024 |
| 10-K | Annual report | Feb 16, 2024 | Dec 31, 2023 |
| DFAN14A | Filing | Feb 15, 2024 | — |
| DFAN14A | Filing | Jan 29, 2024 | — |
| 8-K |
Current report
Results of operations
|
Jan 23, 2024 | Jan 23, 2024 |
| DFAN14A | Filing | Jan 9, 2024 | — |
| DFAN14A | Filing | Jan 8, 2024 | — |
| DEFA14A | Additional proxy material | Jan 8, 2024 | — |
| 8-K |
Current report
Officer or director change
|
Dec 5, 2023 | Nov 30, 2023 |
| 8-K |
Current report
Other events
|
Dec 5, 2023 | Dec 5, 2023 |
| 8-K |
Current report
Other events
|
Nov 30, 2023 | Nov 30, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 27, 2023 | Nov 21, 2023 |
| 10-Q | Quarterly report | Oct 27, 2023 | Oct 1, 2023 |
| 8-K |
Current report
Officer or director change
|
Oct 23, 2023 | Oct 20, 2023 |
| 8-K |
Current report
Results of operations
|
Oct 17, 2023 | Oct 17, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 30, 2023 | Aug 30, 2023 |
| 8-K |
Current report
Acquisition or sale of assets
|
Aug 25, 2023 | Aug 23, 2023 |
| SC TO-I/A | Filing | Aug 23, 2023 | — |
| 425 | Filing | Aug 23, 2023 | — |
| SC TO-I/A | Filing | Aug 21, 2023 | — |
| 425 | Filing | Aug 21, 2023 | — |
| 425 | Filing | Aug 18, 2023 | — |
| 425 | Filing | Aug 17, 2023 | — |
| SC TO-I/A | Filing | Aug 17, 2023 | — |
| 425 | Filing | Aug 17, 2023 | — |
| 425 | Filing | Aug 17, 2023 | — |
| 425 | Filing | Aug 16, 2023 | — |
| 425 | Filing | Aug 15, 2023 | — |
| 425 | Filing | Aug 14, 2023 | — |
| 425 | Filing | Aug 11, 2023 | — |
| 425 | Filing | Aug 10, 2023 | — |
| 425 | Filing | Aug 9, 2023 | — |
| 425 | Filing | Aug 8, 2023 | — |
| 425 | Filing | Aug 7, 2023 | — |
| 425 | Filing | Aug 4, 2023 | — |
| 425 | Filing | Aug 3, 2023 | — |
| 425 | Filing | Aug 3, 2023 | — |
| SC TO-I/A | Filing | Aug 3, 2023 | — |
| 425 | Filing | Aug 2, 2023 | — |
| 425 | Filing | Aug 1, 2023 | — |
| 425 | Filing | Jul 31, 2023 | — |
| 10-Q | Quarterly report | Jul 31, 2023 | Jul 2, 2023 |
| 425 | Filing | Jul 31, 2023 | — |
| 425 | Filing | Jul 28, 2023 | — |
| 425 | Filing | Jul 28, 2023 | — |
| 425 | Filing | Jul 28, 2023 | — |
| 425 | Filing | Jul 28, 2023 | — |
| 8-K | Current report | Jul 28, 2023 | Jul 28, 2023 |
| 425 | Filing | Jul 27, 2023 | — |
| 425 | Filing | Jul 27, 2023 | — |
| 425 | Filing | Jul 26, 2023 | — |
| 425 | Filing | Jul 26, 2023 | — |
| 425 | Filing | Jul 25, 2023 | — |
| 425 | Filing | Jul 25, 2023 | — |
| 425 | Filing | Jul 25, 2023 | — |
| 425 | Filing | Jul 25, 2023 | — |
| 425 | Filing | Jul 25, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| SC TO-I | Filing | Jul 24, 2023 | — |
| 425 | Filing | Jul 24, 2023 | — |
| 8-K |
Current report
Other events
|
Jul 24, 2023 | Jul 24, 2023 |
| 425 | Filing | Jul 20, 2023 | — |
| 425 | Filing | Jul 20, 2023 | — |
| 425 | Filing | Jul 20, 2023 | — |
| 425 | Filing | Jul 20, 2023 | — |
| 425 | Filing | Jul 20, 2023 | — |
| 8-K |
Current report
Results of operations
|
Jul 20, 2023 | Jul 20, 2023 |
| 11-K | Employee savings plan report | Jun 26, 2023 | Dec 31, 2022 |
| 11-K | Employee savings plan report | Jun 26, 2023 | Dec 31, 2022 |
| SD | Specialized disclosure (conflict minerals) | May 24, 2023 | — |
| 8-K |
Current report
Material agreement
|
May 8, 2023 | May 3, 2023 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 1, 2023 | Apr 27, 2023 |
| 10-Q | Quarterly report | Apr 28, 2023 | Apr 2, 2023 |
| DEFA14A | Additional proxy material | Apr 19, 2023 | — |
| 8-K |
Current report
Results of operations, Other events
|
Apr 18, 2023 | Apr 18, 2023 |
| DEFA14A | Additional proxy material | Apr 13, 2023 | — |
| PX14A6G | Filing | Apr 12, 2023 | — |
| PX14A6G | Filing | Apr 10, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 4, 2023 | Apr 4, 2023 |
| 8-K |
Current report
Officer or director change
|
Apr 3, 2023 | Mar 31, 2023 |
| DEFA14A | Additional proxy material | Mar 28, 2023 | — |
| PX14A6G | Filing | Mar 22, 2023 | — |
| ARS | Annual report to shareholders | Mar 16, 2023 | Jan 1, 2023 |
| DEFA14A | Additional proxy material | Mar 15, 2023 | — |
| DEFA14A | Additional proxy material | Mar 15, 2023 | — |
| DEF 14A | Proxy statement | Mar 15, 2023 | — |
| S-3ASR | Automatic shelf registration | Feb 16, 2023 | — |
| 10-K | Annual report | Feb 16, 2023 | Jan 1, 2023 |
| 8-K/A |
Amended current report
Officer or director change
|
Feb 15, 2023 | Feb 14, 2023 |
| 8-K |
Current report
Officer or director change
|
Feb 14, 2023 | Feb 14, 2023 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JNJ (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- NJ
- Headquarters
- New Brunswick, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 200406
- Former names
- JOHNSON & JOHNSON ET AL (until Jan 23, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.